Analyst historically most in tune with the company
Apr 26, 2015 14:48:44 GMT -5
liane, otherottawaguy, and 6 more like this
Post by joeypotsandpans on Apr 26, 2015 14:48:44 GMT -5
Of all the analysts that I've read with the history of the company, I believe that Keith Markey from Griffin Securities is the most "in tune" with the company and seems to be the most "connected" IMO. Here is his update from late Feb. and when reading it you can see he was right on with the early adopters, the higher dosage (12unit), and most likely the additional lines/capacity. Lets hope he is as spot on with his most recent price target 
Lets revisit:
February 25, 2015 8:59 AM EST
Griffin Securities analyst Keith Markey reiterated a Buy rating and $16.25 price target on MannKind (NASDAQ: MNKD) as Afrezza debuts and the strategic plans emerge.
Markey commented, "It’s still too early to get a read on uptake of the inhalable insulin, since it’s been on the market for little more than two weeks. We believe the initial demand is coming from diabetics who participated in the clinical trials and others who became aware of the drug’s unique attributes well before launch. By mid-year, sales should benefit from the marketing support, a larger dosage strength should be available, and favorable reimbursement policies should be in place. In preparation, MannKind is adding fill & finish production lines that will more than triple its production capacity in the June quarter."
The analyst also note the R&D pipeline will be refilled soon as MannKind plans to develop Technosphere formulations of active pharmaceutical ingredients in three areas: pulmonary disease, pain, and cancer supportive care.
Meanwhile, Operations performed in line with expectations to close out an eventful year and the Company will probably refinance debt that is coming due in August.
Link to article:
www.streetinsider.com/Analyst+Comments/Griffin+Securities+Maintains+Bullish+View+on+MannKind+%28MNKD%29+as+Afrezza+Debuts+and+Strategic+Plans+Emerge/10310043.html?si_client=intbro
Lets revisit:February 25, 2015 8:59 AM EST
Griffin Securities analyst Keith Markey reiterated a Buy rating and $16.25 price target on MannKind (NASDAQ: MNKD) as Afrezza debuts and the strategic plans emerge.
Markey commented, "It’s still too early to get a read on uptake of the inhalable insulin, since it’s been on the market for little more than two weeks. We believe the initial demand is coming from diabetics who participated in the clinical trials and others who became aware of the drug’s unique attributes well before launch. By mid-year, sales should benefit from the marketing support, a larger dosage strength should be available, and favorable reimbursement policies should be in place. In preparation, MannKind is adding fill & finish production lines that will more than triple its production capacity in the June quarter."
The analyst also note the R&D pipeline will be refilled soon as MannKind plans to develop Technosphere formulations of active pharmaceutical ingredients in three areas: pulmonary disease, pain, and cancer supportive care.
Meanwhile, Operations performed in line with expectations to close out an eventful year and the Company will probably refinance debt that is coming due in August.
Link to article:
www.streetinsider.com/Analyst+Comments/Griffin+Securities+Maintains+Bullish+View+on+MannKind+%28MNKD%29+as+Afrezza+Debuts+and+Strategic+Plans+Emerge/10310043.html?si_client=intbro
